Rate My Professor Philip Andrews

His research interests encompass main group organometallic chemistry, including novel chiral complexes for asymmetric synthesis and heavy p-block metal complexes; medicinal chemistry focused on bioactive bismuth compounds for anti-inflammatory, anti-tumour, and anti-microbial applications, as well as metallo-drugs against Leishmania; medical imaging using bismuth and rare-earth contrast agents; and green chemistry through solvent-free syntheses and sustainable catalysts. As a founding member of the Monash Centre to Impact Antimicrobial Resistance since 2020, he contributes to industry engagement. Notable publications include 'Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles' (2021), 'Leishmaniasis: current treatment and prospects for new drugs and vaccines' (2009), and 'Metal compounds against neglected tropical diseases' (2018). With 196 research articles, he leads projects such as the ARC Training Centre for Development of Advanced Radiochemical Technologies and Combating Antimicrobial Resistance with Bismuth, Gallium, and Indium.